Birnbaum Michael, Sharif Zafar
St. Luke's-Roosevelt Hospital Center, 1111 Amsterdam Ave, New York, NY, USA;
Patient Prefer Adherence. 2008 Feb 2;2:233-40. doi: 10.2147/ppa.s3346.
Antipsychotic medications provide the foundation for treatment of acute exacerbations as well as relapse prevention in patients with schizophrenia as demonstrated by rigorous placebo-controlled trials. However, despite their proven effectiveness, poor adherence to prescribed antipsychotic regimens remains the most important driver of suboptimal clinical outcomes in this population. This paper reviews the magnitude of the problem of medication non-adherence in patients with schizophrenia and the various factors that contribute to non-adherence, with particular emphasis on factors related to antipsychotic medications. The profile of the latest atypical antipsychotic, paliperidone extended-release (ER) tablets, is then reviewed and the implications of its unique pharmacokinetic profile for adherence in this patient population are discussed.
抗精神病药物为精神分裂症患者急性发作的治疗以及复发预防提供了基础,这已被严格的安慰剂对照试验所证实。然而,尽管其疗效已得到证实,但对规定的抗精神病治疗方案依从性差仍然是该人群临床效果欠佳的最重要原因。本文回顾了精神分裂症患者药物不依从问题的严重程度以及导致不依从的各种因素,特别强调了与抗精神病药物相关的因素。随后,对最新的非典型抗精神病药物帕利哌酮缓释片的情况进行了回顾,并讨论了其独特的药代动力学特征对该患者群体依从性的影响。